Inventor · disambiguated record
Cynthia Bamdad
Also filed as: BAMDAD CYNTHIA · BAMDAD CYNTHIA C · BAMDAD CYNTHIA CAROL
46 granted patents·73 pending applications·1,473 citations·filing 1994–2025
98Inventor score
Files withMINERVA BIOTECHNOLOGIES CORP84BAMDAD CYNTHIA C14HARVARD COLLEGE5CLINICAL MICRO SENSORS INC2OSMETECH TECHNOLOGY INC2
Top patents by PatentIndex Score
119 records- 0197US6541617B1Detection of target analytes using particles and electrodesCLINICAL MICRO SENSORS INC·Filed 1999·Granted Apr 1, 2003·179 cites·13 claims
- 0296US12115192B2Chimeric antigen receptor compositions and methods for treating MUC1* diseasesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Granted Oct 15, 2024·3 cites·39 claims
- 0396US12049618B2Method for making pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2020·Granted Jul 30, 2024·3 cites·18 claims
- 0496US11976295B2Media for stem cell proliferation and inductionMINERVA BIOTECHNOLOGIES CORP·Filed 2023·Granted May 7, 2024·4 cites·19 claims
- 0596US8501921B2Detection of target analytes using particles and electrodesBAMDAD CYNTHIA C·Filed 2007·Granted Aug 6, 2013·22 cites·4 claims
- 0696US5620850AMolecular recognition at surfaces derivatized with self-assembled monolayersHARVARD COLLEGE·Filed 1994·Granted Apr 15, 1997·612 cites·28 claims
- 0795US12351646B2Diagnostic methods using anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Granted Jul 8, 2025·1 cites·16 claims
- 0895US12195728B2Method for making pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Granted Jan 14, 2025·1 cites·6 claims
- 0995US12049514B2Anti-NME antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Jul 30, 2024·3 cites·16 claims
- 1095US12037413B2Anti-NME antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Jul 16, 2024·3 cites·28 claims
- 1195US12006371B2Humanized anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2022·Granted Jun 11, 2024·3 cites·29 claims
- 1295US11976132B2Diagnostic methods using anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2019·Granted May 7, 2024·5 cites·18 claims
- 1395US11897967B2Humanized anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2022·Granted Feb 13, 2024·3 cites·30 claims
- 1495US6809196B2Molecular recognition at surfaces derivatized with self-assembled monolayersHARVARD COLLEGE·Filed 2001·Granted Oct 26, 2004·71 cites·14 claims
- 1595US6197515B1Molecular recognition at surfaces derivatized with self-assembled monolayersUNIV HARVARD·Filed 1999·Granted Mar 6, 2001·153 cites·13 claims
- 1694US12202799B2Agents for differentiating stem cells and treating cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Jan 21, 2025·2 cites·18 claims
- 1794US11746159B2Humanized anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2016·Granted Sep 5, 2023·8 cites·13 claims
- 1893US8535944B2Culturing embryonic stem cells, embryonic stem-like cells, or induced pluripotent stem cells with a Muc1 or Muc1* ligandBAMDAD CYNTHIA C·Filed 2010·Granted Sep 17, 2013·17 cites·36 claims
- 1993US8012743B2Detection of target analytes using particles and electrodesOSMETECH TECHNOLOGY INC·Filed 2001·Granted Sep 6, 2011·38 cites·8 claims
- 2092US11931347B2Method of screening for agents for differentiating stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2016·Granted Mar 19, 2024·5 cites·21 claims
- 2190US10703821B2Method for stimulating or enhancing proliferation of cells by activating the mucin 1 (MUC1) receptorMINERVA BIOTECHNOLOGIES CORP·Filed 2014·Granted Jul 7, 2020·5 cites·15 claims
- 2290US9932407B2Stem cell enhancing therapeuticsMINERVA BIOTECHNOLOGIES CORP·Filed 2015·Granted Apr 3, 2018·8 cites·38 claims
- 2390US8859495B2Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptorsBAMDAD CYNTHIA C·Filed 2006·Granted Oct 14, 2014·13 cites·40 claims
- 2489US11560435B2MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2019·Granted Jan 24, 2023·4 cites·17 claims
- 2589US10724027B2Method for making pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2013·Granted Jul 28, 2020·4 cites·6 claims
- 2688US12104170B2Methods for deriving dopaminergic neurons from pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Oct 1, 2024·2 cites·37 claims
- 2788US11702483B2Method of treating an NME7 expressing cancer with a peptideMINERVA BIOTECHNOLOGIES CORP·Filed 2018·Granted Jul 18, 2023·2 cites·7 claims
- 2888US8344113B2Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2010·Granted Jan 1, 2013·8 cites·13 claims
- 2988US2025067746A1Methods for culturing stem and progenitor cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 3087US11591565B2Media for stem cell proliferation and inductionMINERVA BIOTECHNOLOGIES CORP·Filed 2014·Granted Feb 28, 2023·5 cites·19 claims
- 3187US2024277803A1Nme inhibitors and methods of using nme inhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 3286US6322979B1Molecular recognition at surfaces derivatized with self-assembled monolayersHARVARD COLLEGE·Filed 1999·Granted Nov 27, 2001·54 cites·14 claims
- 3386US2025066505A1Diagnostic methods using anti-muc1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 3485US10421819B2MUC1* antibodiesBAMDAD CYNTHIA C·Filed 2009·Granted Sep 24, 2019·7 cites·20 claims
- 3584US11202775B2Methods for treatment of cancerBAMDAD CYNTHIA C·Filed 2008·Granted Dec 21, 2021·2 cites·20 claims
- 3684US6306584B1Electronic-property probing of biological molecules at surfacesHARVARD COLLEGE·Filed 1997·Granted Oct 23, 2001·90 cites·12 claims
- 3784US2025026853A1Humanized anti-muc1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 3881US12415868B1Anti-NME antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Granted Sep 16, 2025·0 cites·9 claims
- 3981US2024409515A1Agents for differentiating stem cells and treating cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 4081US2024424025A1Chimeric antigen receptor compositions and methods for treating muc1* diseasesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 4180US2024307359A1Method of screening for agents for differentiating stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 4280US2024392038A1Anti-nme antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 4380US2024294590A1Nucleic acid encoding genetically engineered growth factor variantsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 4479US2022193270A1Method for enhancing tumor growthMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 4579US2024261406A1Chimeric antigen receptor compositions and methods for treating muc1* diseasesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 4678US7615340B2Electronic detection of interaction and detection of interaction based on the interruption of flowMINERVA BIOTECHNOLOGIES CORP·Filed 2001·Granted Nov 10, 2009·11 cites·58 claims
- 4778US2022218846A1Nme inhibitors and methods of using nme inhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 4876US2022089779A1Nme inhibitors and methods of using nme inhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 4976US2024299507A1Humanized anti-muc1* antibodies and direct use of cleavage enzymeMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 5076US2022252604A1Methods for culturing stem and progenitor cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
Showing the top 50 of 119 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →